We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Diagnostic Assay Platform to Fasten Response Time to Emerging Pandemic Situations

By LabMedica International staff writers
Posted on 07 Feb 2023
Print article
Image: A collaborative project aims to deliver an innovative diagnostic platform for fast pandemic responsiveness (Photo courtesy of Clickmer)
Image: A collaborative project aims to deliver an innovative diagnostic platform for fast pandemic responsiveness (Photo courtesy of Clickmer)

The COVID-19 pandemic brought about a health crisis that highlighted severe fragilities within the healthcare sector, including lack of preparedness. In order to reduce vulnerability to future pandemics, there is a need for a large-scale, coordinated and comprehensive health response. Now, a new project aims to establish a diagnostic assay platform that can enable a faster response time during emerging pandemics.

A collaboration project, InfektoFlex, launched by Clickmer Systems (Manchester, UK) and Fraunhofer IMS (Duisburg, Germany) has received a EURO 1.1 million grant to develop an innovative diagnostic platform for fast pandemic responsiveness. The project which is due to commence in spring 2023 aims to establish a novel diagnostic assay platform that can enable a fast response time towards emerging pandemic situations. In the collaboration, Clickmers will be being combined with optical nanosensors, to develop a diagnostic assay platform with superior sensitivity and specificity having a faster response time for the detection of societal relevant emerging pathogens. Clickmers are synthetic antibody analogues that can bind to targets with high specificity and affinity. Optical nanosensors, which are fluorescent in near infrared light, qualify for low signal-to-noise ratio. Upon binding of a pathogen to the detection structure, the fluorescence of the nanosensor changes, thereby enabling measurement of the binding events.

“We are excited to launch the project InfektoFlex with Fraunhofer IMS. The platform will provide a more cost-efficient and time-saving solution, with a reduction in development costs through a more sustainable process compared to the commonly used ELISA assay systems (which require the usage of animal-derived antibodies),” said Dr. Ian Kavanagh, COO of APIS Assay Technologies. “Clickmer Systems will provide an adaptive and innovative diagnostic platform for pandemic responsiveness with higher reproducibility.”

Related Links:
Clickmer Systems 
Fraunhofer IMS 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.